These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21075029)

  • 1. QM methods in structure based design: utility in probing protein-ligand interactions.
    Gleeson MP; Hannongbua S; Gleeson D
    J Mol Graph Model; 2010 Dec; 29(4):507-17. PubMed ID: 21075029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QM/MM as a tool in fragment based drug discovery. A cross-docking, rescoring study of kinase inhibitors.
    Gleeson MP; Gleeson D
    J Chem Inf Model; 2009 Jun; 49(6):1437-48. PubMed ID: 19459698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study.
    Panigrahi SK
    Amino Acids; 2008 May; 34(4):617-33. PubMed ID: 18180869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase inhibitors and the case for CH...O hydrogen bonds in protein-ligand binding.
    Pierce AC; Sandretto KL; Bemis GW
    Proteins; 2002 Dec; 49(4):567-76. PubMed ID: 12402365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the enthalpic contribution to ligand binding using QM calculations: effect of methodology on geometries and interaction energies.
    Gleeson D; Tehan B; Gleeson MP; Limtrakul J
    Org Biomol Chem; 2012 Sep; 10(35):7053-61. PubMed ID: 22858758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacophore map of small molecule protein kinase inhibitors.
    McGregor MJ
    J Chem Inf Model; 2007; 47(6):2374-82. PubMed ID: 17941626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halogen bonding--a novel interaction for rational drug design?
    Lu Y; Shi T; Wang Y; Yang H; Yan X; Luo X; Jiang H; Zhu W
    J Med Chem; 2009 May; 52(9):2854-62. PubMed ID: 19358610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine bonding--how does it work in protein-ligand interactions?
    Zhou P; Zou J; Tian F; Shang Z
    J Chem Inf Model; 2009 Oct; 49(10):2344-55. PubMed ID: 19788294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are AM1 ligand-protein binding enthalpies good enough for use in the rational design of new drugs?
    Villar R; Gil MJ; García JI; Martínez-Merino V
    J Comput Chem; 2005 Oct; 26(13):1347-58. PubMed ID: 16021597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CORES: an automated method for generating three-dimensional models of protein/ligand complexes.
    Hare BJ; Walters WP; Caron PR; Bemis GW
    J Med Chem; 2004 Sep; 47(19):4731-40. PubMed ID: 15341488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
    Deng Z; Chuaqui C; Singh J
    J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases.
    Meshkat S; Klon AE; Zou J; Wiseman JS; Konteatis Z
    J Chem Inf Model; 2011 Jan; 51(1):52-60. PubMed ID: 21117680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
    Caballero J; Alzate-Morales JH; Vergara-Jaque A
    J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate assessment of the strain energy in a protein-bound drug using QM/MM X-ray refinement and converged quantum chemistry.
    Fu Z; Li X; Merz KM
    J Comput Chem; 2011 Sep; 32(12):2587-97. PubMed ID: 21598285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
    Chuaqui C; Deng Z; Singh J
    J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DrugScore(CSD)-knowledge-based scoring function derived from small molecule crystal data with superior recognition rate of near-native ligand poses and better affinity prediction.
    Velec HF; Gohlke H; Klebe G
    J Med Chem; 2005 Oct; 48(20):6296-303. PubMed ID: 16190756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SuperStar: comparison of CSD and PDB-based interaction fields as a basis for the prediction of protein-ligand interactions.
    Boer DR; Kroon J; Cole JC; Smith B; Verdonk ML
    J Mol Biol; 2001 Sep; 312(1):275-87. PubMed ID: 11545602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein flexibility in ligand docking and virtual screening to protein kinases.
    Cavasotto CN; Abagyan RA
    J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge-based scoring functions in drug design. 1. Developing a target-specific method for kinase-ligand interactions.
    Xue M; Zheng M; Xiong B; Li Y; Jiang H; Shen J
    J Chem Inf Model; 2010 Aug; 50(8):1378-86. PubMed ID: 20681607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. kinDOCK: a tool for comparative docking of protein kinase ligands.
    Martin L; Catherinot V; Labesse G
    Nucleic Acids Res; 2006 Jul; 34(Web Server issue):W325-9. PubMed ID: 16845019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.